Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), today announced that management will be participating in the Benzinga Cannabis Capital Conference being held October 14 -15, 2021 in person at the Marriott Marquis in New York City and virtually.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism. For further information about Anebulo, please visit www.anebulo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005012/en/
Contacts
Anebulo Pharmaceuticals, Inc.
Rex Merchant
Chief Financial Officer
(512) 598-0931
IR@anebulo.com
LHA Investor Relations
Yvonne Briggs
(310) 691-7100
ybriggs@lhai.com
Source: Anebulo Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20211005005012/en
